STAAR Surgical Company (NASDAQ:STAA) Q4 2023 Earnings Conference Call February 26, 2024 4:15 PM ET Company Participants Brian Moore - Vice President-Investor Relations & Corporate Development Tom Frinzi - President & Chief Executive Officer Patrick Williams - Chief Financial Officer. Conference Call Participants Patrick Wood - Morgan Stanley John Young - Canaccord Margaret Andrew - William Blair George Sellers - Stephens Inc. Ryan Zimmerman - BTIG Anthony Petrone - Mizuho Group Matthew O'Brien - Piper Sandl ...

Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 29, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-11634 UNITED STATES SECURITIES AND EXCHANGE COMMISSION STAAR Surgical Company (Exact Name of Registrant as Specified in its Charter) (State or Other Jurisdiction of Incorporation or Organization) 25651 Atlan ...

STAAR Surgical Company (NASDAQ:STAA) Q3 2023 Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants Brian Moore - Vice President-Investor Relations & Corporate Development Tom Frinzi - President & Chief Executive Officer Patrick Williams - Chief Financial Officer. Conference Call Participants Anthony Petrone - Mizuho Xuyang Li - Jefferies John Young - Canaccord George Sellers - Stephens Margaret Kaczor Andrew - William Blair Steve Lichtman - Oppenheimer Operator Good day ladies and gentle ...

Financial Data and Key Metrics Changes - Total net sales for Q2 2023 were $92.3 million, up 14% compared to $81.1 million in Q2 2022 and up 26% sequentially from Q1 2023 [7] - Gross profit for Q2 2023 was $70.7 million, or 76.6% of net sales, compared to $63.9 million, or 78.8% of net sales in Q2 2022 [93] - Operating income in Q2 2023 was $8.6 million, or 9.3% of net sales, down from $17 million, or 21% of net sales in Q2 2022 [95] Business Line Data and Key Metrics Changes - ICL sales increased by $50 million, or 19%, year-over-year, while other product sales decreased by $4 million [7] - ICL sales for Q2 2023 were $93.1 million, with global ICL sales growth of 19% and unit growth of 21% [117] - Research and development expense was $11.8 million in Q2 2023, up from $8.6 million in Q2 2022 [9] Market Data and Key Metrics Changes - Sales in the EMEA region declined by 9% due to macroeconomic and geopolitical factors, but ICL units in European markets increased by 6% [4] - APAC region saw a 29% increase in ICL units and a 26% increase in sales for Q2 2023 [117] - The U.S. refractive market experienced a 15% year-over-year decline, while STAAR's ICL sales grew by 10% [91][67] Company Strategy and Development Direction - The company aims to remain a high-growth organization, targeting 20% annual growth, particularly in APAC and the U.S. [6][16] - New analytic tools are being implemented to better target high-volume customers and improve marketing effectiveness [5] - A patient call center education and surgeon referral program is being piloted to enhance patient engagement and conversion [5] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the U.S. market despite current challenges, emphasizing the need for time to transition EVO from a niche to a mainstream procedure [13] - The company anticipates a strong performance in China, with a positive start to the peak season for ICLs [16][61] - Management acknowledged the need for adjustments in digital marketing strategies due to lower-than-expected returns [122] Other Important Information - The company expects to invest approximately $26 million in property and equipment for the year, primarily for manufacturing capacity expansion [10] - The effective tax rate is expected to be approximately 35% in Q3 and Q4 due to reduced profitability in the U.S. [123] Q&A Session Summary Question: What is the outlook for the U.S. market? - Management indicated that the U.S. market is expected to remain flat in the second half of the year, with plans to enhance training and education efforts to drive growth in 2024 [104][132] Question: How is the company addressing the challenges in digital marketing? - The company is reducing digital marketing investments until they can ensure better patient conversion rates and cost-effectiveness [122] Question: What is the confidence level regarding growth in China? - Management expressed high confidence in the Chinese market, noting strong surgeon support and positive sales activity [61][68]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-11634 STAAR Surgical Company (Exact Name of Registrant as Specified in its Charter) Delaware 95-3797439 (State or Other Jurisdiction of (I.R.S. Employer Incorporat ...

STAAR Surgical Company (NASDAQ:STAA) Q1 2023 Earnings Conference Call May 3, 2023 4:30 PM ET Company Participants Brian Moore - VP of Investor, Media Relations and Corporate Development Tom Frinzi - President and CEO Patrick Williams - CFO Conference Call Participants Anthony Petrone - Mizuho Group Margaret Kaczor - William Blair Samuel Durno - BTIG John Young - Canaccord Yang Li - Jefferies David Saxon - Needham Ron Feiner - Oppenheimer Harrison Parsons - Stephens Inc. Tom Stephan - Stifel Jim Sidoti - Sid ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-11634 (State or Other Jurisdiction of Incorporation or Organization) 25651 Atlantic Ocean Drive Lake Forest, California 92630 (Address of Principal Executive Of i ...

Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 30, 2022 For the transition period from to Commission file number: 0-11634 STAAR SURGICAL COMPANY (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or o ...

STAAR Surgical Company (NASDAQ:STAA) Q4 2022 Earnings Conference Call February 21, 2023 4:30 PM ET Company Participants Brian Moore - Vice President of Investor, Media Relations & Corporate Development Tom Frinzi - President, Chief Executive Officer & Chairman Patrick Williams - Chief Financial Officer Conference Call Participants Margaret Kaczor - William Blair Anthony Petrone - Mizuho Zach Weiner - Jefferies David Saxon - Needham Thomas Stephan - Stifel Ryan Zimmerman - BTIG Operator Good day, ladies and ...

Financial Data and Key Metrics Changes - Total net sales for Q3 2022 were $76 million, up 30% compared to $58.4 million in Q3 2021, with a 33% increase in ICL sales, representing 95% of total net sales [20][28] - Gross profit was $60.5 million or 79.5% of net sales, compared to 77.6% in Q3 2021, reflecting a 190 basis point year-over-year increase [23] - Operating income was $13.7 million or 18% of net sales, compared to $7.8 million or 13.4% in Q3 2021 [27] Business Line Data and Key Metrics Changes - Global ICL unit growth was up 40% year-over-year, with significant growth in the U.S. (63%), China (52%), Japan (40%), and South Korea (49%) [9][13] - ICL sales are anticipated to be approximately $272 million for fiscal 2022, representing 28% year-over-year growth [10] Market Data and Key Metrics Changes - In China, the company expects to exceed a 25% share of the refractive surgery market units by year-end, despite COVID-related delays [10] - The U.S. market is projected to see unit growth accelerate to approximately 100% year-over-year in Q4 2022 [18] Company Strategy and Development Direction - The company is focusing on the growth opportunities with its premium EVO products while phasing out its low-margin other products business [11][19] - STAAR aims to achieve approximately 30% ICL sales growth year-over-year to approximately $355 million in total company net sales for fiscal 2023 [12][32] Management's Comments on Operating Environment and Future Outlook - Management highlighted challenges such as tighter COVID restrictions in China and macroeconomic headwinds in Europe but remains optimistic about growth in the U.S. and Asia [10][12] - The company anticipates a strong trajectory of growth for EVO ICL and continued market share gains in 2023 [19][32] Other Important Information - The company has trained over 550 U.S. surgeons on EVO lenses and expects to exceed its goal of training 600 by the end of 2022 [16][18] - STAAR has implemented an investment policy to maximize returns on cash, resulting in a cash balance of $224.7 million as of September 30, 2022 [29][30] Q&A Session Summary Question: What are the headwinds affecting the Q4 implied outlook? - Management identified approximately $5 million in delayed revenue due to COVID lockdowns in China, $2 million from European macroeconomic factors, and $1.5 million from foreign exchange impacts [38] Question: What is the expected growth in China for 2023? - Management expects unit growth in China to exceed 30% in 2023, despite lingering COVID headwinds [41] Question: How is the U.S. market performing? - The U.S. market is expected to see strong growth, with management projecting significant market share gains within 18 months [42] Question: What is the impact of the phase-out of other products on ICL use? - Management does not anticipate a negative impact on ICL use due to the phase-out of other products, as they will continue to support customers during the transition [57] Question: How does the company expect to achieve the $355 million target for 2023? - The target includes a mix of unit growth and pricing, with expectations for a healthy average selling price in the U.S. [72]